PDCD1 and neoplasm: For instance, certain studies employed the CRISPER/Cas9-mediated knockout of PD-1 and other ICIs (TRACK, B2M, and DGK) in CAR T-cells targeting EGFRvIII in glioblastoma, resulting in improved anti-tumor responses [208, 209].